[go: up one dir, main page]

CL2018001133A1 - Faecalibacterium prausnitzii y desulfovibrio piger para uso en el tratamiento o prevención de la diabetes y enfermedades intestinales - Google Patents

Faecalibacterium prausnitzii y desulfovibrio piger para uso en el tratamiento o prevención de la diabetes y enfermedades intestinales

Info

Publication number
CL2018001133A1
CL2018001133A1 CL2018001133A CL2018001133A CL2018001133A1 CL 2018001133 A1 CL2018001133 A1 CL 2018001133A1 CL 2018001133 A CL2018001133 A CL 2018001133A CL 2018001133 A CL2018001133 A CL 2018001133A CL 2018001133 A1 CL2018001133 A1 CL 2018001133A1
Authority
CL
Chile
Prior art keywords
prevention
faecalibacterium prausnitzii
treatment
diabetes
intestinal diseases
Prior art date
Application number
CL2018001133A
Other languages
English (en)
Inventor
Muhammad-Tanweer Khan
Fredrik Bäckhed
Original Assignee
Metabogen Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabogen Ab filed Critical Metabogen Ab
Publication of CL2018001133A1 publication Critical patent/CL2018001133A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)

Abstract

<p>La presente invención se refiere, en general, al área de la medicina. Más específicamente, la invención se refiere al uso de bacterias probióticas sinérgicas como intervención para la salud. En particular, la presente invención proporciona una cepa de <em>Faecalibacterium prausnitzii </em>y una cepa bacteriana que tiene una o más de las características de: (i) ser productora de acetato, (ii) ser consumidora de lactato y (iii) tener la capacidad de ser un aceptor de electrones, para uso en el tratamiento o prevención de una enfermedad asociada con niveles reducidos de butirato o una enfermedad asociada con un número reducido o bajo de bacterias <em>Faecalibacterium prausnitzii</em>. </p>
CL2018001133A 2015-10-28 2018-04-27 Faecalibacterium prausnitzii y desulfovibrio piger para uso en el tratamiento o prevención de la diabetes y enfermedades intestinales CL2018001133A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1519088.7A GB201519088D0 (en) 2015-10-28 2015-10-28 The use of bacteria formulations

Publications (1)

Publication Number Publication Date
CL2018001133A1 true CL2018001133A1 (es) 2018-06-15

Family

ID=55130365

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001133A CL2018001133A1 (es) 2015-10-28 2018-04-27 Faecalibacterium prausnitzii y desulfovibrio piger para uso en el tratamiento o prevención de la diabetes y enfermedades intestinales

Country Status (17)

Country Link
US (2) US11260082B2 (es)
EP (1) EP3368053A1 (es)
JP (1) JP7018396B2 (es)
KR (2) KR20180070698A (es)
CN (2) CN115778986A (es)
AU (1) AU2016344770B2 (es)
BR (1) BR112018008312B1 (es)
CA (1) CA3002603A1 (es)
CL (1) CL2018001133A1 (es)
GB (1) GB201519088D0 (es)
IL (1) IL258881B2 (es)
MX (1) MX392357B (es)
RU (1) RU2754367C2 (es)
SG (1) SG11201803062XA (es)
UA (1) UA124926C2 (es)
WO (1) WO2017072278A1 (es)
ZA (1) ZA201802585B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11959125B2 (en) * 2016-09-15 2024-04-16 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
MY201921A (en) 2017-06-16 2024-03-23 Biofermin Pharmaceutical Co Ltd Agent for preventing or treating fat-associated diseases and/or inflammation
AU2018313765A1 (en) * 2017-08-07 2020-02-27 Finch Therapeutics, Inc. Compositions and methods for decolonizing antibotic-resistant bacteria in the gut
US11491192B2 (en) 2018-01-09 2022-11-08 The Cleveland Clinic Foundation Treatment and prevention of pathogenic bacterial overgrowth using butyrate-producing bacteria
US20210393737A1 (en) * 2018-09-25 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mam polypeptides for the treatment of obesity and obesity-related disorders
CN110878349A (zh) * 2019-12-06 2020-03-13 深圳谱元科技有限公司 终末期肾病生物标志物及其应用
EP3858363A1 (en) * 2020-01-28 2021-08-04 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Composition for treating intestinal or pulmonary diseases
AU2021228209A1 (en) * 2020-02-28 2022-08-11 Stichting Amsterdam UMC Intervention strategy for prevention or treatment of Diabetes mellitus, autoimmune disease, inflammatory disease or cardiovascular disease
NL2025020B1 (en) * 2020-02-28 2021-10-14 Acad Medisch Ct Intervention strategy for prevention or treatment of autoimmune diseases
KR102169795B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 eb-fpdk9 균주 및 그의 용도
KR102169794B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도
KR102185828B1 (ko) * 2020-08-26 2020-12-03 주식회사 엔테로바이옴 피칼리박테리움 프로스니치 균주를 포함하는 아토피성 질환 예방 또는 치료용 약학적 조성물
KR102245415B1 (ko) * 2020-12-14 2021-04-29 주식회사 엔테로바이옴 피칼리박테리움 프로스니치 균주 배양 배지 조성물
JP2024518270A (ja) * 2021-05-06 2024-05-01 ソシエテ・デ・プロデュイ・ネスレ・エス・アー イノシトール、エリスリトール、又はソルビトールのうちの少なくとも１つを使用した、フィーカリバクテリウム・プラウスニッツィイの生育を増進するための組成物及び方法
CN113201575A (zh) * 2021-05-11 2021-08-03 西安医学院第一附属医院 基于普氏粪杆菌对动物肾脏炎症反应变化影响的研究方法
CN113797232B (zh) * 2021-10-28 2023-05-26 南昌大学 具有缓解胰岛素抵抗功能的组合物及其应用
CN114304380A (zh) * 2022-01-13 2022-04-12 合肥河川生物医药科技有限公司 普拉梭菌在猪鸡上的应用
CN117384867B (zh) * 2022-09-16 2024-06-07 北京普译生物科技有限公司 一种经修饰的Cas3移位酶及其应用
CN117016672A (zh) * 2023-08-29 2023-11-10 天晴干细胞股份有限公司 一种诱导2型糖尿病饲料及其在建立2型糖尿病动物模型中的应用
CN118845848B (zh) * 2024-07-01 2025-10-17 温州大学 普氏粪杆菌dsm 17677在制备防治猪流行性腹泻病毒感染产品中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2006102350A1 (en) * 2005-03-23 2006-09-28 Washington University In St. Louis The use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
JP2007189947A (ja) * 2006-01-19 2007-08-02 Gifu Univ 硫化水素産生菌抑制剤及び硫化水素産生菌抑制方法
BR112014010660A2 (pt) * 2011-11-04 2017-05-09 Gen Mills Inc métodos e composições para modular bactéria gastrointestinal
US9314494B2 (en) * 2012-05-25 2016-04-19 The United States Of America, As Represented By The Secretary Of Agriculture Cranberry xyloglucan oligosaccharide composition
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
HK1214954A1 (zh) 2013-03-05 2016-08-12 格罗宁根大学 Faecalibacterium prausnitzii htf-f(dsm26943)在抑制炎症中的应用
BR112015023124A2 (pt) * 2013-03-14 2017-07-18 Therabiome Llc liberação de organismos probióticos e/ou agentes terapêuticos almejada para o trato gastrintestinal
CA2903053C (en) * 2013-03-15 2023-01-17 Amyris, Inc. Use of phosphoketolase and phosphotransacetylase for production of acetyl-coenzyme a derived compounds
US20150246081A1 (en) * 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
WO2019036176A1 (en) * 2017-08-14 2019-02-21 uBiome, Inc. METHOD OF CHARACTERIZING THE MICROBIOMA ASSOCIATED WITH A DISEASE

Also Published As

Publication number Publication date
CN108367030A (zh) 2018-08-03
SG11201803062XA (en) 2018-05-30
RU2021113597A (ru) 2021-06-25
ZA201802585B (en) 2019-07-31
JP2018532779A (ja) 2018-11-08
UA124926C2 (uk) 2021-12-15
IL258881A (en) 2018-06-28
WO2017072278A1 (en) 2017-05-04
BR112018008312A2 (pt) 2018-10-30
US20220133814A1 (en) 2022-05-05
CN115778986A (zh) 2023-03-14
US12318412B2 (en) 2025-06-03
US11260082B2 (en) 2022-03-01
MX2018005261A (es) 2019-07-04
AU2016344770A1 (en) 2018-05-10
MX392357B (es) 2025-03-24
KR20180070698A (ko) 2018-06-26
US20200405777A1 (en) 2020-12-31
CA3002603A1 (en) 2017-05-04
KR102371868B1 (ko) 2022-03-07
HK1257739A1 (zh) 2019-10-25
GB201519088D0 (en) 2015-12-09
AU2016344770A2 (en) 2018-05-17
IL258881B1 (en) 2023-07-01
RU2018119309A (ru) 2019-11-28
BR112018008312B1 (pt) 2023-11-07
WO2017072278A8 (en) 2017-12-07
CN108367030B (zh) 2022-12-27
RU2754367C2 (ru) 2021-09-01
IL258881B2 (en) 2023-11-01
KR20210000758A (ko) 2021-01-05
RU2021113597A3 (es) 2021-10-27
JP7018396B2 (ja) 2022-02-10
AU2016344770B2 (en) 2023-07-13
EP3368053A1 (en) 2018-09-05
RU2018119309A3 (es) 2020-03-26

Similar Documents

Publication Publication Date Title
CL2018001133A1 (es) Faecalibacterium prausnitzii y desulfovibrio piger para uso en el tratamiento o prevención de la diabetes y enfermedades intestinales
de Almada et al. Paraprobiotics: Evidences on their ability to modify biological responses, inactivation methods and perspectives on their application in foods
MX2019014045A (es) Composiciones y metodos.
ES2408279R1 (es) Bacteria acido lactica probiotica
MX375509B (es) Empleo de una composición que comprende microorganismos para aumentar la producción intestinal de ácido butírico, ácido fólico o niacina y/o disminuir la producción intestinal de ácido succínico.
AR106768A1 (es) Composiciones que comprenden cepas bacterianas
MX2016006708A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
EA201792547A1 (ru) Популяции бактерий для стимуляции состояния здоровья
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112014030434A2 (pt) método não terapêutico; uso de uma proteína; composição nutricional; e uso da composição nutricional
MX2011010930A (es) Modulacion de respuestas inflamatorias a través de factor xi.
BR112012033212A2 (pt) uso de lactobacillo inibindo a produção de gás de bactéria coliforme isolada em infantes afetados por cólica
MX353230B (es) Un bacteriofago para biocontrol de salmonella y en la preparacion o procesamiento de alimentos.
BR112017014649A2 (pt) ?isolado intestinal humano, e, composição?
MX2022011742A (es) Composicion nutritiva para el entorno gastrointestinal para proporcionar microbioma y perfil metabolico mejorados.
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
MX2017016283A (es) Lactobacillus paracasei para la produccion de acido linoleico conjugado, preparaciones nutricionales y farmaceuticas que lo contienen y sus usos.
BR112017023636A2 (pt) suplemento dietético
PE20141452A1 (es) Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmaceuticas que las usan
BR112017011850A2 (pt) métodos e reagentes para detectar neisseria gonorrhoeae e seus determinantes de resistência antimicrobiana
MX2017002385A (es) Metodos y reactivos para la prevencion y/o el tratamiento de infecciones.
CL2016000746A1 (es) Un método para producir un l-aminoácido usando una bacteria de la familia de las enterobacteriaceae teniendo atenuada la expresión de un gen que codifica un transportador de fosfato
CL2017001818A1 (es) Bacteria de ácido láctico y su uso para el tratamiento de mastitis
BR112014004123A2 (pt) micro-organismos das espécies bacteroides xylanisolvens